Page 94 - Read Online

Onzi et al. Hepatoma Res 2019;5:7 I http://dx.doi.org/10.20517/2394-5079.2018.114 Page 5 of 7

patients justifying that the large population of NAFL/NASH patients makes systematic surveillance
impracticable [4,12,35] .

CONCLUSION
With increasing cure rates for chronic liver disease related to HBV and HCV, NASH may become the leading
cause of HCC and liver transplantation in the coming decades. Recent evidence shows that a significant
proportion of patients with NAFL and NASH progresses to HCC even in the absence of cirrhosis or fibrosis.
However, new effective monitoring and screening measures should be established to address these high-risk
patients, thereby reducing the future impact of HCC in this population.

DECLARATIONS
Authors’ contributions
Conception and design of the study, data analysis and interpretation: Onzi G, Moretti F, Soldera J
Data acquisition, provided administrative, technical, and material support: Onzi G, Moretti F, Soldera J,
Balbinot RA, Balbinot SS

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, et al. Systematic review with meta-analysis: risk of hepatocellular
carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-
703.
2. Cholankeril G, Patel R, Khurana S, Satapathy SK. Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and
implications for management. World J Hepatol 2017;9:533-43.
3. Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, et al. Does hepatocellular carcinoma in non-alcoholic steatohepatitis
exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 2009;42:958-62.
4. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European
Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic
fatty liver disease. J Hepatol 2016;64:1388-402.
5. Oda K, Uto H, Mawatari S, Ido A. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a
review of human studies. Clin J Gastroenterol 2015;8:1-9.
6. Chu H, Williams B, Schnabl B. Gut microbiota, fatty liver disease, and hepatocellular carcinoma. Liver Res 2018;2:43-51.
7. Perumpail RB, Wong RJ, Ahmed A, Harrison SA. Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver
disease and the metabolic syndrome: US experience. Dig Dis Sci 2015;60:3142-8.
8. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic
steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009;24:248-54.
9. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, et al. The incidence and risk factors of hepatocellular carcinoma in